| 血清CC-16水平用于ARDS患者预后的临床价值研究 |
| 投稿时间：2016-10-29 修订日期：2016-11-08 点此下载全文 |
| 引用本文：吕丽辉,杨玉波,付言杰,胡振杰,庄志雄,陈玺卿.血清CC-16水平用于ARDS患者预后的临床价值研究[J].医学研究杂志,2017,46(7):140-145 |
| DOI：
10.11969/j.issn.1673-548X.2017.07.035 |
| 摘要点击次数: 1135 |
| 全文下载次数: 681 |
|
|
| 中文摘要:目的 探讨血清Clara细胞分泌蛋白-16（Clara cell protein-16，CC-16）水平用于急性呼吸窘迫综合征患者短期预后的临床价值。方法 纳入2014年4月~2016年4月住院的ARDS患者97例，根据ARDS严重程度分为轻度ARDS组（n=28）、中度ARDS组（n=33）及重度ARDS组（n=36）。根据住院30天病死情况，分为生存组（n=57）及病死组（n=40）。所有患者入院时检测常规实验室指标及血清CC-16水平，记录APACHEⅡ及SOFA评分。ROC曲线检测CC-16、APACHEⅡ及SOFA评分的预后价值。结果 不同严重程度ARDS患者血清CC-16水平由高至低分别为重度ARDS组（27.33±8.14ng/ml）、中度ARDS组（20.27±6.97ng/ml）及轻度ARDS组（13.87±5.23ng/ml）。住院30天内病死的ARDS患者基线血清CC-16水平显著高于生存患者（24.98±8.33 vs 18.03±8.05，P=0.000）。CC-16单独使用的AUC为0.782（95%CI：0.691~0.872），CC-16联合APACHEⅡ及SOFA评分的 AUC为0.811（95%CI：0.728~0.895）。基线血清CC-16水平较低（<18.78ng/ml）患者30天总体生存率显著高于CC-16水平较高（≥ 18.78ng/ml）的患者（83.7% vs 38.9%，P=0.000）。结论 血清CC-16水平可作为ARDS患者短期病死情况的预后指标。 |
| 中文关键词:急性呼吸窘迫综合征 Clara细胞分泌蛋白-16 急性生理与慢性健康评分Ⅱ 序贯器官衰竭评分 预后 |
| |
| Clinical Research of Prognostic Value of Serum CC-16 Levels in Patients with ARDS |
|
|
| Abstract:Objective To investigate the prognosis value of serum Clara cell protain-16 (CC-16) levels in patients with acute respiratory distress syndrome (ARDS). Methods A total of 97 patients with ARDS from April 2013 to April 2016 were enrolled, and they were divided into mild ARDS (n=28), moderate ARDS (n=33) and severe ARDS (n=36) group. According to the 30-day mortality, patients were divided into survival group (n=57) and death group (n=40). The routine laboratory parameters, serum CC-16 levels, APACHEⅡ score and SOFA scores were recorded. ROC curve was used to evaluate the prognostic value of CC-16 combined with APACHEⅡand(or) SOFA score. Results The CC-16 levels in patients with ARDS from highest to lowest were:severe ARDS group (27.33±8.14ng/ml), moderate ARDS group (20.27±6.97ng/ml) and mild ARDS group (13.87±5.23ng/ml). The baseline CC-16 levels in death group were significantly higher than survival group (24.98±8.33 vs 18.03±8.05ng/ml, P=0.000). The AUC of CC-16 used for prognosis in ARDS patients was 0.782 (95%CI:0.691-0.872) alone, and the AUC of CC-16 combined with APACHEⅡand SOFA score was 0.811 (95%CI:0.728-0.895). The 30-day overall survival in patients with low baseline serum CC-16 level(<18.78ng/ml) was significant higher than patients with high CC-16 level (≥ 18.78ng/ml) (83.7% vs 38.9%, P=0.000). Conclusion Serum CC-16 can be used as a useful prognostic indicator for short-term outcome in patients with ARDS. |
| keywords:Acute respiratory distress syndrome Clara cell protein-16 Acute physiology,chronic health evaluation Ⅱ score Sequential organ failure assessment Prognosis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
